Results 11 to 20 of about 240,114 (259)

The heterogeneity of Parkinson’s disease

Journal of Neural Transmission, 2023
AbstractThe heterogeneity of Parkinson’s disease (PD), i.e. the various clinical phenotypes, pathological findings, genetic predispositions and probably also the various implicated pathophysiological pathways pose a major challenge for future research projects and therapeutic trail design.
Ullrich Wüllner, Per Borghammer, Chi-un Choe, Ilona Csoti, Björn Falkenburger, Thomas Gasser, Paul Lingor, Peter Riederer   +7 more
openaire   +4 more sources

Parkinson's disease dementia: a neural networks perspective. [PDF]

, 2015
In the long-term, with progression of the illness, Parkinson's disease dementia affects up to 90% of patients with Parkinson's disease. With increasing life expectancy in western countries, Parkinson's disease dementia is set to become even more ...
Foltynie, T, Gratwicke, J, Jahanshahi, M
core   +1 more source

Noradrenaline and Parkinson's Disease [PDF]

Frontiers in Systems Neuroscience, 2011
Parkinson's disease (PD) is characterized by the degeneration of dopamine (DA) neurons in the substantia nigra pars compacta, and motor symptoms including bradykinesia, rigidity, and tremor at rest. These symptoms are exhibited when striatal dopamine concentration has decreased by around 70%.
Claire eDelaville, Philippe eDe Deurwaerdère, Abdelhamid eBenazzouz, Abdelhamid eBenazzouz   +3 more
openaire   +5 more sources

The competitive NMDA antagonist CPP protects substantia nigra neurons from MPTP-induced degeneration in primates [PDF]

, 1993
Degeneration of nigrostriatal dopaminergic neurons is the primary histopathological feature of Parkinson's disease. The neurotoxin MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) induces a neurological syndrome in man and non-human primates very ...
Burg, M., Horowski, R., Kalveram, K. T., Lange, Klaus W., Löschmann, P. A., Riederer, Peter, Sofic, E., Wachtel, H.   +7 more
core   +1 more source

Methamphetamine and Parkinson's Disease [PDF]

Parkinson's Disease, 2013
Parkinson's disease (PD) is a neurodegenerative disorder predominantly affecting the elderly. The aetiology of the disease is not known, but age and environmental factors play an important role. Although more than a dozen gene mutations associated with familial forms of Parkinson's disease have been described, fewer than 10% of all cases can be ...
Rosario Moratalla, Rosario Moratalla, Sara Ares-Santos, Sara Ares-Santos, Noelia Granado, Noelia Granado, Noelia Granado   +6 more
openaire   +5 more sources

Abnormal temporal coupling of tactile perception and motor action in Parkinson's disease [PDF]

, 2017
Evidence shows altered somatosensory temporal discrimination threshold (STDT) in Parkinson's disease in comparison to normal subjects. In healthy subjects, movement execution modulates STDT values through mechanisms of sensory gating.
Baione, Viola, Battista, Emanuele, Belvisi, Daniele, Berardelli, Alfredo, Conte, Antonella, Cortese, FRANCESCA NATALIA, Fabbrini, Giovanni, Tartaglia, Matteo, Zhu, Xiao Y.   +8 more
core   +1 more source

Parkinson's disease: autoimmunity and neuroinflammation [PDF]

, 2016
Parkinson's disease is a neurodegenerative disease that causes the death of dopaminergic neurons in the substantia nigra. The resulting dopamine deficiency in the basal ganglia leads to a movement disorder that is characterized by classical parkinsonian ...
CINIGLIO APPIANI, MARIO, CONTE, MICHELA, DE VINCENTIIS, Marco, DE VIRGILIO, ARMANDO, FABBRINI, Giovanni, GALLO, Andrea, GRECO, Antonio, INGHILLERI, Maurizio, RIZZO, MARIA IDA, ROSATO, CHIARA   +9 more
core   +1 more source

Primary skin fibroblasts as a model of Parkinson's disease [PDF]

, 2012
Parkinson's disease is the second most frequent neurodegenerative disorder. While most cases occur sporadic mutations in a growing number of genes including Parkin (PARK2) and PINK1 (PARK6) have been associated with the disease.
A Grunewald, A Grunewald, A Petit, A Rakovic, A Sajadi, A Sprenger, AL Fridman, AL Fridman, AW Michell, B Stefano Di, Blas Morales-Gordo, C Mytilineou, C Piccoli, CA Costa da, CM Clements, DP Narendra, DT Woodley, E Fernandez-Espejo, EM Valente, F Pan-Montojo, F Soldner, FR Wiedemann, G Tesco, Georg Auburger, GP Connolly, H Braak, H Jiang, H Mortiboys, Heinz Reichmann, HH Hoepken, HH Hoepken, HM Huang, HM Huang, IF Khan, IH Park, J Hoenicka, J Waak, Jessica Drost, JM Harper, K Bayreuther, K Gorner, K Isobe, K Winkler-Stuck, Katrin Marcus, KH Narsinh, L Gasparini, L Grandoso, LS Tain, M Garcia-Arencibia, M Ikemura, M Jendrach, M Klinkenberg, M Sun, M Varma, M Wernig, Marina Jendrach, MB Graeber, MC Maj, Michael Klinkenberg, N Exner, N Hirashima, O Rothfuss, P Hoyo del, P Rieske, R Djaldetti, R Musanti, S Geisler, S Gispert, S Kaneko, S Mai, SM Hussein, Suzana Gispert, T Amo, T Gasser, T Shishido, Ulrich Brandt, Vania Broccoli, WG Tatton, Wolfram S. Kunz, WY Lee, Y Miki, Y Ren, Y Ren, YC Kim, Z Jingzhong   +84 more
core   +1 more source

Imaging in Parkinson's Disease [PDF]

Clinical Medicine, 2016
Parkinson's disease (PD) is a chronic neurodegenerative disease characterized by the loss of nigrostriatal dopaminergic neurons and aggregation of misfolded α-synuclein in Lewy bodies. The underlying mechanisms of neurodegeneration in PD are still unknown, and there are no disease-modifying treatments to slow the neurodegenerative processes.
Politis, Marios, Pagano, Gennaro, Niccolini, Flavia   +2 more
openaire   +7 more sources

Characterization of vitamin D supplementation and clinical outcomes in a large cohort of early Parkinson's disease. [PDF]

, 2018
BackgroundVitamin D (VitD) deficiency is common in Parkinson's disease (PD) and has been raised as a possible PD risk factor. In the past decade, VitD supplementation for potential prevention of age related conditions has become more common.
Christine, Chadwick W, Kim, Soeun, Luthra, Nijee S, NINDS NET-PD Investigators, Zhang, Yunxi   +4 more
core   +2 more sources